Not actual patients.
Designed to fit
your lifestyle
Why HYMPAVZI?
Learn what sets HYMPAVZI apart.
Prefilled pen. Fixed dose.* Once weekly
HYMPAVZI comes ready to use; there’s no measuring. No mixing. No reconstitution.
Innovative approach to hemophilia treatment
HYMPAVZI works to help achieve hemostasis (how your body stops or prevents bleeding) through rebalancing.
Delivered bleed protection
HYMPAVZI was shown to help protect patients from bleeds.†
No treatment-related lab monitoring required
HYMPAVZI does not require lab monitoring before or during treatment. Make sure to talk to your doctor about lab monitoring that may be necessary for your condition.
- Your first dose (loading dose) of HYMPAVZI is 300 mg (two 150 mg injections). Then you will inject a weekly (maintenance) dose as prescribed by your healthcare provider.
- In the BASIS phase 3 study, the primary objective was to measure the annualized bleed rate (ABR) of treated bleeds vs on-demand factor-based treatment and vs factor-based prophylaxis after 12 months on HYMPAVZI. 92% reduction in treated bleeds on HYMPAVZI compared with on-demand factor-based treatment (3.18 ABR vs 38.00 ABR). 35% reduction in treated bleeds on HYMPAVZI compared with routine prophylaxis treatment (5.08 ABR vs 7.85 ABR). Individual results may vary.
Download the patient brochure to find out how HYMPAVZI fits your lifestyle.
Learn how HYMPAVZI works